Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: August 24, 2005
Last updated: May 21, 2013
Last verified: May 2013